Interestingly, other modes of CD11b activation as mediated by the more recently developed pharmacological activator leukadherin 1 were demonstrated to yield anti-inflammatory effects in myeloid cells which may be exploited for treatment of autoimmune diseases associated with hyperactive MAC-1 (37). The gene discussed is ITGB2; the disease is autoimmune disease.